Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bevacizumab + carboplatin + hydroxychloroquine + paclitaxel
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of bevacizumab (an anti-angiogenic monoclonal antibody), carboplatin (a platinum-based chemotherapy agent), hydroxychloroquine (an autophagy inhibitor), and paclitaxel (a taxane chemotherapy agent). This regimen has been studied primarily for the treatment of metastatic non-small cell lung cancer (NSCLC), with the addition of hydroxychloroquine to the standard carboplatin, paclitaxel, and bevacizumab combination representing an attempt to overcome chemotherapy resistance through autophagy inhibition.
02
Targets
DNAMicrotubuleVEGFA (Vascular endothelial growth factor A)NeuraminidaseTUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on bevacizumab + carboplatin + hydroxychloroquine + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bevacizumab + carboplatin + hydroxychloroquine + paclitaxel.